Hepatitis C

FDA Approves Mavyret, a Pan-Genotypic Treatment for HCV

By August 03, 2017

Mavyret is a once-daily, ribavirin-free treatment that combines glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

Epclusa Indication Expanded to Include HCV/HIV Co-Infected Patients

By August 02, 2017

The supplemental New Drug Application (sNDA) approval was based on data from the Phase 3 open-label, ASTRAL-5 study.

HCV Eradication Linked to Improved Glycemic Control in Patients with Diabetes

July 07, 2017

Improved glycemic control, reduced antidiabetic medication use with sustained virologic response

Three-Drug Combo Effective for HCV Patients with Limited Retreatment Options

June 01, 2017

Pill (sofosbuvir, velpatasvir, voxilaprevir) is for patients who have failed with direct-acting antivirals

CDC: Maternal HCV Infection Increasing in the U.S.

May 12, 2017

Rural counties seem hardest hit and rates mirror opioid epidemic

Ledipasvir-Sofosbuvir Evaluated in Adolescents with Chronic HCV

January 03, 2017

98 of 100 patients reached sustained virologic response at 12 weeks; no virologic failure observed

HCV Treatment Patterns in Patients With Advanced CKD: 2010 to 2015

By November 14, 2016

Data from a retrospective cohort study presented at The Liver Meeting® 2016 has shown that hepatitis C virus (HCV)-infected patients with advanced chronic kidney disease (CKD) "remains a challenging population to treat," with <10% receiving treatment in the early direct-acting antivirals (DAA) era.

Glecaprevir/Pibrentasvir Achieves High SVR12 Rates in Non-cirrhotic HCV GT 4-6

By November 14, 2016

The all-oral, ribavirin-free glecaprevir/pibrentasvir regimen achieved high SVR12 rates in non-cirrhotic patients with hepatitis C virus (HCV) genotype (GT) 4, 5, and 6 infection, the phase 3 ENDURANCE-4 study concluded at The Liver Meeting® 2016.

DAAs Effective for Chronic HCV, Even in Very Elderly

By November 14, 2016

DAAs are equally highly effective for the treatment of chronic HCV in all age groups, including very elderly patients.

LDV/SOF ± RBV, OPrD Effective in HIV/HCV Co-Infected Veterans

By November 14, 2016

Ledipasvir/Sofosbuvir with or without ribavirin is associated with comparable sustained virologic response (SVR) rates for African American patients and non-African Americans who have HIV/HCV co-infection, but cirrhosis was associated with significantly poorer rates.

High Efficacy, Improved PROs With SOF/VEL in HCV/HIV Co-Infection

By November 13, 2016

Patient-reported outcome scores improve significantly for HIV-HCV co-infected patients undergoing sofosbuvir and velpatasvir therapy.

High Real-World Cure Rates With DAA Combo in HCV With Decompensated Cirrhosis

By November 13, 2016

Patients with HCV GT1 with decompensated cirrhosis treated in the real world with ledipasvir/sofosbuvir plus ribavirin achieved high cure rates and comparable MELD improvement to patients in clinical trials.

Chronic Liver Diseases Now Affect 25% of U.S. Adolescents, Young Adults

By November 11, 2016

The prevalence of chronic liver diseases has more than doubled in the past 30 years among adolescents and young adults in the United States to about 25%, according to research presented at The Liver Meeting® 2016.